Z-VAD-FMK

For research use only.

Catalog No.S7023

552 publications

Z-VAD-FMK Chemical Structure

CAS No. 187389-52-2

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Size Price Stock Quantity  
RMB 962.65 In stock
RMB 3841.92 In stock
RMB 21048.63 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Z-VAD-FMK has been cited by 552 publications

Purity & Quality Control

Choose Selective Caspase Inhibitors

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Features A key compound for apoptosis studies.
Targets
Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro

Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
GC1a Mor1RZBweHSxc3nzJGF{e2G7 NImxe|A2OM7:TR?= NXLhXHVIOjSq MnHlbY5lcWOjdHXzJIEheHKxdHXjeIl3\SCnZn\lZ5Qh[WejaX7zeEBmfG:yb4Pp[IU> M1PqRlI3OTZ7MEe1
HGL5 MVnBdI9xfG:|aYOgRZN{[Xl? MX61NO69VQ>? NF;6T3EzPGh? NVr0fohEcW6maXPheIV{KGFicILveIVkfGm4ZTDl[oZm[3RiYXfhbY5{fCCndH;wc5Nq\GV? M3z2UlI3OTZ7MEe1
HepG2 NInGdZFCeG:ydH;zbZMhSXO|YYm= M{naelIx|ryP NV3XPXZzOWh? M2LD[4F1fGWwdXH0[YQhfGinIHHwc5B1d3SrYzDpcoR2[3Srb36gc4YhUUmLLUGwxsA> NHjIXJozPjF4NEe5OS=>
BEL-7402 MUXBdI9xfG:|aYOgRZN{[Xl? NUn1Wmh7OjEQvF2= MWmxbC=> M4PuOIF1fGWwdXH0[YQhfGinIHHwc5B1d3SrYzDpcoR2[3Srb36gc4YhUUmLLUGwxsA> MXiyOlE3PDd7NR?=
CEF NUL5VGJqU2mwYYPlJGF{e2G7 NE[0d5MxNDN|LE[3MFExOM7:TR?= NIfKNXAyPW2rbh?= M1XIToRwf25vcnXneYxifGW|IGDSJIVvgnmvZTDhZ5Rqfmm2eTD0c{A1OO,:hTDheEAyODEQvF2= NHm5ZnQzPjFyMkOzPS=>
SP2/0 MmriRZBweHSxc3nzJGF{e2G7 MXqxNFDPxE1? MmDuNYg> M4XlN2ROW09? MWXicI9kc3NidHjlJIFxd3C2b4Ppd{Bw\iCVUEKvNEBk\Wyucx?= M3jxT|I3ODd2N{Oy
HUVEC-2c MYHBdI9xfG:|aYOgRZN{[Xl? M1L6eFUx|ryP NXHp[3NMPmh? NGnkTXdl\WO{ZXHz[YQhfGinIH;4MWxFVC2rbnT1Z4VlKGG3dH;wbIFogQ>? MlLxNlYxOjF5Mkm=
U1 M2fPbWFxd3C2b4Ppd{BCe3OjeR?= M2nQbVAuOTByzszN NFfPXlMzcA>? M1fO[5Jm\HWlZYOg[JJ2\y2rbnT1Z4VlKGGyb4D0c5NqeyCjbnSgd5Vje2WzdXXueEBJUVZvMTDy[ZBtcWOjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MlL6NlU6QDB7NEK=
ACH-2 MYDBdI9xfG:|aYOgRZN{[Xl? NIjLNnUxNTJyMN88US=> NH\CSVQzcA>? NULURWJiemWmdXPld{BlenWpLXnu[JVk\WRiYYDvdJRwe2m|IHHu[EB{fWK|ZYH1[Y51KEiLVj2xJJJmeGyrY3H0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1S3R|I2QThyOUSy
U1 NV3YXIJmU2mwYYPlJGF{e2G7 NXrQc|hSOTByzszN MnjMNog> MYDpcohq[mm2czDjZZNx[XOnLUO= MWCyOVk5ODl2Mh?=
A549/V16 M2rlNmFxd3C2b4Ppd{BCe3OjeR?= NIDFN2k2OM7:TR?= MoLXNYg> M2DnTJJmeHKnc4Pld{BVTy:WTT3pcoR2[2WmIHHwc5B1d3Orcx?= NUfsV5FVOjV7NE[wN|M>
SGN MnHaRZBweHSxc3nzJGF{e2G7 M2jkclIxdU1? NU\WNVVJPDiq NUi4XYw4cGG|IH7vJIlv\my3ZX7j[UBwdiCDSV[sJINidHCjaX6g[ZhxemW|c3nvckBweiClZXzsJIFxd3C2b4Ppdy=> NEHocpozPTh5NE[zNy=>
HCT116  NYK3b|NzSXCxcITvd4l{KEG|c3H5 NFjzVJU2OM7:TR?= MVWybC=> M4\RN4lvcGmkaYTzJJRp\SClZXzsJIRm[XSqIHnu[JVk\WRiYomgSGRXWA>? MlntNlU5Pjh6MUi=
DTK-SME MorXRZBweHSxc3nzJGF{e2G7 MoLkOVDPxE1? M1u3[lJp NE[yUJdFVVOR NWfCOpFzeGG{dHnhcIx6KGmwaHnibZR{KHSqZTDhdI9xfG:|aYOgbY5lfWOnZDDifUBjfXCrdnHjZYlv\Q>? Mnv3NlU5PDN6OUe=
HL-60 NVLKTVZtSXCxcITvd4l{KEG|c3H5 MmnHOVDPxE1? M3LCblQ5cA>? Mln5doVlfWOnczDj[YxtKGSnYYToJINifXOnZDDifUBUU0lvSVmgeJJm[XSvZX70xsA> NXjISXYxOjV6MkSwOFM>
U937 M4HsdWFxd3C2b4Ppd{BCe3OjeR?= M3G2elUx|ryP NIjvSHk1QGh? MVry[YR2[2W|IHPlcIwh\GWjdHigZ4F2e2WmIHL5JHNMUS2LSTD0doVifG2nboVCpC=> MXSyOVgzPDB2Mx?=
A549 NEPLVHBCeG:ydH;zbZMhSXO|YYm= NYSz[2REOjBizszN NV7H[4QzOjSq NULlVmVWemWmdXPld{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCKRlPQJJRz\WG2bXXueC=> MXGyOVc6PDF2OR?=
HeLa NEDrXlNCeG:ydH;zbZMhSXO|YYm= MUSxNO69VQ>? NVLCUZVyPDiq Mnzl[IVkdGmwZYOgeIhmKHKjdHWgc4Yh[XCxcITvd4l{KGS{YX3heIlk[WyueR?= NWXYRnlnOjV5N{K1OFU>
SGC-7901 MkL3RZBweHSxc3nzJGF{e2G7 NW\DUHlXOjEEoN88US=> MYmxbC=> Mn36bY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDvfIFtcXCuYYTpci=> MoXyNlU4PjdyN{[=
MCF-7 NWe3[mFMSXCxcITvd4l{KEG|c3H5 MWixNO69VQ>? M3Ltb|Jp MWLpcohq[mm2czD0bIUh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IEPC MmL0NlU4OjJzMUS=
A549 M4i4OWFxd3C2b4Ppd{BCe3OjeR?= MYmxNEDPxE1? MVqyOIg> MYfEUXNQ MVrwdo9ud3SnczDIRmMufHKnYYTl[EBCPTR7IHPlcIwhe3W{dnn2ZYwhLiCjdITlcpVifGW|IITo[UBkdGWjdnXkJHBCWlBiZYjwdoV{e2mxbh?= M3XJblI2Pjh|NU[4
U87 M{HyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUm1NO69VQ>? NHHqSIEycA>? NILtfFNz\WOxdnXyd{Bk\WyuIHfyc5d1cCCocn;tJHROYiC2cnXheI1mdnR? MVSyOVY5OTZ4OB?=
Neocortical Neuron NVz4TJk3VmW3cn;0c5hq[2m2eTDBd5NigQ>? NHP0VpUyODEQvF2= NX;D[|JnOWh? M2fN[4FvfGGpb37pfoV{KEixaXHtbYRmKEFvSX7keYNm\CCQZYXyc5RwgGmlaYT5 MXuyOVY4PTByMR?=
Primary human placental cytotrophoblasts MX;BdI9xfG:|aYOgRZN{[Xl? M3HEfVMx|ryP NFfLUIYzPGh? MXzEUXNQ M2i0b5JmfmW{c3XzJJRp\SCrbnjpZol1cW:wIH;mJFEy|rJvSGPENkBjgSC2cnnjcI9{[W8EoB?= M2TQdFI2PjR{NUmy
MM Mn3rRZBweHSxc3nzJGF{e2G7 NUnKfpRGPTEQvF2= NYe2dI93OjCvaX6= MYfwZZJ1dHliaX7obYJqfHNiU1jLMYlv\HWlZXSgJINmdGxiZHXheIg> NWX2RlhJOjV3M{CwPVg>
DLD1 M4nUZWFxd3C2b4Ppd{BCe3OjeR?= MnfONlDDqM7:TR?= M1TRVVFp MnuwdIFzfGy7IILleoVze2W|IHPlcIwh[XCxcITvd4l{KGOjdYPl[EBjgSCZU2Cx NWLOTm83OjV3MkSyOFY>
MDA-MB-231 NF7qOVFEgXSxdH;4bYNqfHliQYPzZZk> NVnzeXdLOTEQvF2= MV:xbC=> M2S3VoF2\22nboTzJINmdGxiZHXheIgh[W[2ZYKgR2hWSSC2cnXheI1mdnR? MXmyOVUzOTVyMR?=
MKN28 MVPBdI9xfG:|aYOgRZN{[Xl? M{f1[|Ex|ryP NVzE[IlmOzCvaX6= MnzSSG1UVw>? NW\RXGh3cW6qaXLpeJMhXE6ILd8xJJBtfXNiQ1jYMYlv\HWlZXSgZZBweHSxc3nz NFXhU2QzPTVzM{m2NC=>
HL-60 M4j3WmN6fG:2b4jpZ4l1gSCDc4PhfS=> M1T0OlExOM7:TR?= MnnCNYg> M1:wT2ROW09? NEPaNGfDqGmvcILveoV{KH[rYXLpcIl1gSCxZjDUR25Cey22cnXheIVlKGOnbHzz M4PWdVI2PTB{OUOy
AGS M{mxVGFxd3C2b4Ppd{BCe3OjeR?= MYOxNO69VQ>? NYjO[XZtOWh? NYDrNHV5eHKndnXueJMh[3W{Y4XtbY4ucW6mdXPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNuID24MEBidmRiLUmgdJJwfGWrboO= Ml;UNlU1QTJ{MUS=
A549  MWPBdI9xfG:|aYOgRZN{[Xl? MYexNO69VQ>? MV6yOIg> M2HkNYJtd2OtczDEUWFUNWmwZIXj[YQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHHu[EBieG:ydH;0bYMh[2WubDDk[YF1cA>? NF3Yc2MzPTR|NEm4PS=>
INS-1 MkC2RZBweHSxc3nzJGF{e2G7 M1\V[|Ux|ryP NFLBOlU3cA>? NWjO[WQ3TE2VTx?= M17ZSYRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBm[XKueTDhdI9xfG:2aXOgZ4VtdHQEoB?= NU\NV|hxOjV2M{C4PVc>
Primary hepatocytes  MXrBdI9xfG:|aYOgRZN{[Xl? Mon1OVDPxE1? MWSxPIg> NIDKbWtqdmirYnn0d{BieG:ydH;zbZMhd2ZiaHXwZZRw[3m2ZYOgbY5lfWOnZDDifUBC[3RiRDDhcoQhXE6ILd8x MknkNlU1ODd3M{i=
L929-A  NWLy[HdQS3m2b4TvfIlkcXS7IFHzd4F6 NYXEe5RROjEEoN88US=> NIPQe|UzPGh? MlmxbY5pcWKrdIOgWG5H|rFvaX7keYNm\CClZXzsJIRm[XSq MXSyOVM6QDV2MB?=
L929-N MoS2R5l1d3SxeHnjbZR6KEG|c3H5 NVvoRYtyOjEEoN88US=> NUXke|RzOjSq MUjlcohidmOnczDk[YF1cCC4aXGgZZV1d2O{aX7lJHRPTs7zIIDyc4R2[3Srb36= MnrFNlU{QTh3NEC=
Cytotoxicity Assay NYDpb2RuS2WubDDWbYFjcWyrdImgRZN{[Xl? MmDTNlDPxE1? MWq0PIg> M3TMPZBz\X[nboSgUWhOTC2rbnT1Z4VlKGOnbHyg[IVifGh? NYLuZoU{OjV|OUKxNVY>
COS7 M{WyO2tqdmG|ZTDBd5NigQ>? MYmxNO69VQ>? M{DqWFI1cA>? NXWycFBQcW6lcnXhd4V{KGOjc4Dhd4UhOy95IHHjeIl3cXSrZYO= MnHsNlU{QDRyMkW=
COS7 MV\BdI9xfG:|aYOgRZN{[Xl? M1;ydlEx|ryP Ml7OOFhp MVLwZZJ1cWGubImgdJJmfmWwdHXkJGZEOTBzLXnu[JVk\WRiY3XscEBl\WG2aB?= MYGyOVM5PDB{NR?=
A375 NV22bmptSXCxcITvd4l{KEG|c3H5 NEfXT4s{OM7:TR?= NVfRT2hCOmh? MVPwdoV3\W62czD0bIUh\HK3Zz3pcoR2[2WmIGDBVnAh[2ynYY\h[4U> Ml[0NlU{PzZzMUW=
A549 NXPVSJBMSXCxcITvd4l{KEG|c3H5 Mn22OVDPxE1? MV[yOIg> NIX1Nnpz\X[ncoPld{BzcWKxc3;t[UBjcW:pZX7ld4l{KGGwZDDhdI9xfG:|aYOgZ4F2e2WmIHL5JEBEcGmsb37n[IFv NXv1XpNpOjV|NEm3PFE>
A549 M17KUmFxd3C2b4Ppd{BCe3OjeR?= NEWzTYwzNjVvMkZOwG0> M4PNR|Fp MX;k[YNz\WG|ZYOgeIhmKHCxcIXsZZRqd25ib3[gZZBweHSxdHnjJINmdGy|IHTldIVv\CCxbjDjc45k\W62cnH0bY9vew>? NFKxclgzPTN2MkSyOy=>
 NBL-W-S  NGjyfWhCeG:ydH;zbZMhSXO|YYm= MXe1NO69VQ>? NH;POI8ycA>? MYnmeYxtgSC{ZYPjeYV{KGOnbHygeoli[mmuaYT5JIFnfGW{IFfBUnQuPjFidILlZZRu\W62 M3:0S|I2OzJ|MkKy
Caki-1  NWXGeGVWSXCxcITvd4l{KEG|c3H5 M1vEbVQx|ryP M3LCbVQ5cA>? NV2yNZNLemWmdXPld{B1cGViboXtZoVzKG:oIFHucoV5cW5iVj3wc5NqfGm4ZTDj[Yxtew>? MlLvNlUzPzlzOUG=
769-P NGfRW2xCeG:ydH;zbZMhSXO|YYm= NXe2THdsPDEQvF2= M4fWSlQ5cA>? M33UTJJm\HWlZYOgeIhmKG63bXLldkBw\iCDbn7lfIlvKFZvcH;zbZRqfmViY3XscJM> Mnq3NlUzPzlzOUG=
H9c2 MkHBRZBweHSxc3nzJGF{e2G7 M4\2bFUx|ryP NHL6Um8ycA>? MoHUbY5pcWKrdIOgSG9ZNWmwZIXj[YQh[2G|cHHz[UA{KGGldHn2ZZRqd25iYoX0JI5wfCC2aHWgcI9{eyCxZjDj[Yxtew>? M1nZZVI2Ojh|OEG5
K562 NHHRbGdCeG:ydH;zbZMhSXO|YYm= MUC1NO69VQ>? M1;oWlRp NH[4fnZqdmirYnn0d{BL[WNvQT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{ Ml3RNlUzPDF4MUm=
L929 NUXZTmRvSXCxcITvd4l{KEG|c3H5 M2LzZVEx|ryP MU[2bC=> NXjDe|gxcW6mdXPld{Bv\WO{b4D0c5NqeyC5aYToJHRPTg>? NXrqTnZIOjVzOUW2OlA>
A549 NVjR[lVpSXCxcITvd4l{KEG|c3H5 NGrtTI0yOM7:TR?= MV6zbC=> MVry[YR2[2W|IHPlcIwh[XCxcITvd4l{KGOjdYPl[EBjgSCSUWG= NIXIVIYzPTF4MU[5PS=>
MCF-7 MXPBdI9xfG:|aYOgRZN{[Xl? NVfPSXBlOjEQvF2= M{T4dVJp MmnE[IVkemWjc3XzJGtFWi2|aWLORU1qdmS3Y3XkJIFxd3C2b4Ppdy=> Mn7xNlUyQDJ{NEC=
OS MXLBdI9xfG:|aYOgRZN{[Xl? MYGyNE81OM7:TR?= NIKwWmE4Omh? MVzpcohq[mm2czDPV{Bk\WyuII\pZYJqdGm2eTDy[YR2[3Srb36gZpkhSzZiY3XyZY1q\GV? MmeyNlUyPTJ|OUm=
HUVECs NWW0eIN6SXCxcITvd4l{KEG|c3H5 MUexNO69VQ>? NVLoOHMyOmh? M2rJW:KhcW6qaXLpeJMh[XCxcITvd4l{KGGwZDDmZYNqdGm2YYTld{BifXSxcHjh[5khcW5iRFXOWlIucW6oZXP0[YQhUFWYRVPz MlX2NlUyOzh5MEO=
EA.hy926 MUPBdI9xfG:|aYOgRZN{[Xl? M4\CfVEx|ryP MXqybC=> M3PscuKhcW6qaXLpeJMh[XCxcITvd4l{KGGwZDDmZYNqdGm2YYTld{BifXSxcHjh[5khcW5iRFXOWlIucW6oZXP0[YQhTUFwaIm5NlY> NFz1SoYzPTF|OEewNy=>
Ebs Mm\wRZBweHSxc3nzJGF{e2G7 MVOxNE0yODEQvF2= NI\kNVQzPGh? NFPU[ZnDqE2PVGOg[4Vv\XKjdHnvckBz[XSnIHTlZ5Jm[XOnZDDhd{B1cGViY3;uZ4VvfHKjdHnvckBw\iC8LW\BSE5ndWtiaX7jdoVie2Wm NF33NnQzPTF|NEixOy=>
Jurkat MX\BdI9xfG:|aYOgRZN{[Xl? NYq3SJgzOjEQvF2= NX7YXlN5OjSq MkTwSG1UVw>? NHz0Rmpx[XK2aXHscJkhcW6qaXLpeEBk\WyuIHTlZZRpKG:oIFr1dotifCClZXzsd{BqdmS3Y3XkJIJ6KDFyMEW4MWY1KGOxbXLpcoVlKHerdHigWnBCyqB? NWrUfplHOjVzMkC3NlM>
K562 NIraepRCeG:ydH;zbZMhSXO|YYm= MU[wMlEuOc7:TR?= MnrWNYg> MkjZbY5pcWKrdIOgZ4xm[X[jZ3Wgc4YhUFOSOUCgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NWfTUZBkOjVzMUmxPFg>
IMR-32 NIDKXYtCeG:ydH;zbZMhSXO|YYm= NWTsdmlMPDEEoN88UeKh NXnaT5JDOmh? MlLK[IVkemWjc3WgbY4h[XCxcITveIlkKGOnbHzzJINwdXCjcnXkJJRwKFRvMjD0c5hqdg>? NV3WdVVjOjVyOES3OVU>
RPMI 8226 NWfObZV1SXCxcITvd4l{KEG|c3H5 MX2xNFDPxE1? NFPNOXoycA>? MXvhcI1we3RiY3;tdIxmfGWueTDicI9kc3NiY3XscEBl\WG2aDDjZZV{\WRiYomgcoVkem:|dHH0bY4uOQ>? M{P3dFI2ODN5OEWx
U266  M3uw[WFxd3C2b4Ppd{BCe3OjeR?= NIHQ[lQyODEQvF2= M2XsNlFp NX3QZYk{eGG{dHnhcIx6KGKub3Prd{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCwZXPyc5N1[XSrbj2x NYHu[msxOjVyM{e4OVE>
H929  NUCwbWF5SXCxcITvd4l{KEG|c3H5 NX;Ue2l4OTByzszN Mn75NYg> NXe4dJVQeGG{dHnhcIx6KGKub3Prd{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCwZXPyc5N1[XSrbj2x MXiyOVA{Pzh3MR?=
MM.1S  M{XGPWFxd3C2b4Ppd{BCe3OjeR?= MlrSNVAx|ryP M3nYflFp Ml7N[YZncWOrZX70cJkheHKndnXueJMhe2:{YX\lcoljNWmwZIXj[YQh[2WubDDk[YF1cCClb33ibY5mKHerdHigcoVkem:|dHH0bY4uOQ>? NULx[lRKOjVyM{e4OVE>
C6 NX;nWmYzSXCxcITvd4l{KEG|c3H5 MVu1NO69VQ>? MVS0PIg> MVvwdoV3\W62czD0bIUhdG:|czDv[kBk\WyuII\pZYJqdGm2eTDjZZV{\WRiYomgdJJm\26nbn;sc45m Ml\YNlUxOTN2N{m=
AGS NVLMcnFuSXCxcITvd4l{KEG|c3H5 M2r5RlUx|ryP MUKyOIg> M{jLPYFjd2yrc3jzJO6zNWyjcHHjbI9v\S2rbnT1Z4VlKGOnbHyg[IVifGhiYX7kJIlvcGmkaYTl[EBoem:5dHi= M3zNdlI2ODB7Nkm4
HeLa  NYfoWGZ5SXCxcITvd4l{KEG|c3H5 NHLwWXo1OM7:TR?= Mn7pNlRp NIPxNIRqdmirYnn0d{B1cGViaX7jdoVie2WmIHHwc5B1d3OrczDpcoR2[2WmIHL5JJNqWk6IMUKx NGHPd4YzPDl{OE[4OS=>
THP-1  M4nnPGFxd3C2b4Ppd{BCe3OjeR?= NH;YUXUyOM7:TR?= NVG3UZpPOWh? MknLdoVlfWOnczDhdI9xfG:|aYOgbY5lfWOnZDDifUBCVEFvU1TUxsA> M{\h[FI1QTJ|NkWz
P815  NGr2WIlCeG:ydH;zbZMhSXO|YYm= NF3MeZoyODBiwsXN NG\rXm8yOmh? MlLiSG1UVw>? MUXpcohq[mm2czD2bZJ2ey2rbnT1Z4VlKGGyb4D0c5Nqew>? NIjiUIIzPDl{M{K3Ny=>
HCT116 NHnKbZRCeG:ydH;zbZMhSXO|YYm= NIPiWIszOM7:TR?= MXqyOIg> NHvpPGVi[nKxZ3H0[ZMhd2ZiVGGtbY5lfWOnZDDhdI9xfG:|aR?= NVjZVXNVOjR6OUC0OFk>
SW1116  MVPBdI9xfG:|aYOgRZN{[Xl? NUPZRlhSOTBiwsXN NX7qe2pOOWh? NXrYNZF2TE2VTx?= NWC1fIxPemW|dILhbY5{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkh\2WoaYTpcoljKHCudYOg[IVkcXSjYnnu[S=> MnPrNlQ5PzR{OE[=
LOVO MY\BdI9xfG:|aYOgRZN{[Xl? MlP2NVAhyrWP NVj6V5VYOWh? NXH3W2hzTE2VTx?= M176V5Jme3S{YXnud{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JIdm\mm2aX7pZkBxdHW|IHTlZ4l1[WKrbnW= MUCyOFg4PDJ6Nh?=
SNU449  M3;pRmFxd3C2b4Ppd{BCe3OjeR?= MlzsNlDPxE1? NXnh[ZdKPDiq NXTLfXAzTE2VTx?= NHvrRYdl\WO{ZXHz[ZMhdWmULUS1NU1qdmS3Y3XkJIFxd3C2b4TpZy=> Mn;aNlQ5PDF4M{i=
Caco-2 NGL3enRCeG:ydH;zbZMhSXO|YYm= MY[0NQKBkc7:TR?= NHjJRlQ1cA>? M4nUU5Bz\X[nboTzJHNVNTdvaX7keYNm\CCcTz2xJINp[W6pZYOgZY5lKFSHUjDkdo9x Mn2zNlQ5OjJzOEO=
macrophage NXHxWFJwS2WubDDWbYFjcWyrdImgRZN{[Xl? NHvvU|MxNTJyMN88US=> M4G5SlI1cA>? M3TXW4lv\HWlZYOgWG5HNSCjbnSgVolxOy2mZYDlcoRmdnRibnXjdo9xfG:|aYOgbY4hdWGlcn;wbIFo\Q>? NIrKZ3ozPDd7OUW2OS=>
AGS  NY[0NFQzSXCxcITvd4l{KEG|c3H5 MmrFNlDPxE1? MkKxNVJp MVTEUXNQ NYXXVnJIemWmdXPld{B1cGViaX7keYN1cW:wIH;mJIFxd3C2b4Ppd{BqdiC{ZYPwc45{\SC2bzD0bIUhTXSRQXOg[pJi[3Srb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGPST|IzPDd6OUewNy=>
LCC9  MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlLFNVAx|ryP M2LSclVl MXjicI9kc3NiY3XscEBl\WG2aDDpcoR2[2WmIHL5JINwdWKrbnH0bY9vKExzNzDhcoQh[2iub4LvdZVqdmV? M4S4PFI1Pzh3MkW2
U937  MXHu[YNzd3C2b4Ppd{BCe3OjeR?= MXmxNOKh|ryP MXWzNOKhdWmw M1rEXYlv\HWlZYOgcoVkem:ydH;zbZMh[2:vYnnu[UB4cXSqIGTOSi=> MlP1NlQ4PzN5NU[=
T cell MYrD[YxtKHC{b3zp[oVz[XSrb36gZZN{[Xl? MYOwMVExOM7:TR?= NHrNPIs4Omh? MonXTWM2OD15MDFOwG0tKGmwaHnibZR{KGGwdHmtR2Q{NWmwZIXj[YQhXCClZXzsJJBzd2yrZnXyZZRqd25iaX6gVGJOS3N? M{TaOVI1PzZ6N{C3
HeLa  MVTBdI9xfG:|aYOgRZN{[Xl? MYW1NO69VQ>? MXK3Nog> NWfWdolNTE2VTx?= MWnwdoV3\W62czDhdI9xfG:|aYOgbY5lfWOnZDDifUBkd22yb4Xu[JPDqDIkgKO1 M1\Gb|I1PzV2N{i2
HeLa  NEniN5lCeG:ydH;zbZMhSXO|YYm= M4nYUlExOM7:TR?= NVrNXW97OjSq MXjzeZBxemW|c3XzJJJifGVib3[gZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KG:4ZYLlfJBz\XO|aX;uJI9nKEd3OWOgc5IhTzdzUjDwNVUx\2y3ZXVCpC=> MXeyOFczOjR4OB?=
IEC-6  MYrBdI9xfG:|aYOgRZN{[Xl? MYqxNO69VQ>? NHHKOW4zPGh? MXfwdoV3\W62czDUZ4RCNWmwZIXj[YQh[2G|cHHz[U0{KGOuZXH2ZYdmKGGwZDFOtk1k[XSnbnnuJIRm\3KjZHH0bY9v NXn6SGljOjR5MUG1O|E>
HCT116 NEPLPVRCeG:ydH;zbZMhSXO|YYm= MYeyNO69VQ>? NWT5XnRJOjSq MkfXbY5pcWKrdIOgeIhmKGOnbHygZZBweHSxdHnjJIlv\HWlZXSgZpkhYUyWMkC1 M33CWFI1PzF|OEGy
L02 MWTBdI9xfG:|aYOgRZN{[Xl? NHnUNHozOM7:TR?= NETld3MycA>? Mkm1dJJmfmWwdIOgeIhmKGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhVUWKUB?= M{T1XlI1PzB4NE[x
A375 MnXRRZBweHSxc3nzJGF{e2G7 NVHrWWVuOjEQvF2= MUCyOIg> MXXy[ZZmenOnczDkbYNqfHKrbn;u[UBDNWmwZIXj[YQh[XCxcITvd4l{ M{DKfVI1Pjl7MUGx
HDPC NIi0VmtCeG:ydH;zbZMhSXO|YYm= Ml3aOVDDvU1? MXKyOIg> M1zMfIlvcGmkaYTzJG5QNWmwZIXj[YQh[XCxcITvd4l{ MmDkNlQ3OzR3OUO=
A549 MlrBRZBweHSxc3nzJGF{e2G7 M2nqZlUxyrWP M2rpZVJp NULVcWhnTE2VTx?= M2nX[5Bz\X[nboTzJJRp\SCqeYDv[IlxdG:rZDDEUmEh[2:wdHXueEBxcGG|ZTDpcoR2[2WmIHL5JINmeGijbH;jbJJwdWmw M3HKe|I1PTh6MUO1
 BV-2 NWXGNnk5SXCxcITvd4l{KEG|c3H5 NGnSZVgzOM7:TR?= Mnz3Nog> Mnzhd5VxeHKnc4Pld{BWXi2rbnT1Z4VlKGOqcn;tZZRqdiCneITyeZNqd25iYX7kJIRqdGG2aX;uJI9nKHSqZTDueYNt\WG{IHXueoVtd3Cn NIPGS3ozPDV3OEGxPC=>
HT-29  MUjBdI9xfG:|aYOgRZN{[Xl? NVTRR5dpPTEQvF2= NHm5W|Q1QGh? MWDicI9kc3NidHjlJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGujZX3w[oVzd2x? M{LrTVI1PTR7MUe1
A549 NVzFVmNJSXCxcITvd4l{KEG|c3H5 NV;CW3ZUPc7:TR?= MoGwNlRp NVTBSHFke3WycILld5NmeyB4ZdMgLGJMOTByNECpMYlv\HWlZXSgZZBweHSxc3nzxsA> MXGyOFUzQTh5MR?=
MIA-PaCa-2 NVnhTlExSXCxcITvd4l{KEG|c3H5 NFLheIkzPGh? NUnWTHd7[myxY3vzJINt\WG4YXflJI9nKGOjc4Dhd4UuOyCrbnT1Z4VlKGK7IHLveIghSS12NEO2OVQh[W6mIIDhZ4xqfGG6ZXy= NIH6dJIzPDVzMEm5Ni=>
Caki-1 M4rWNGFxd3C2b4Ppd{BCe3OjeR?= NVnMNFQ{OjEQvF2= NWTtbIoyOWh? MojpbY5pcWKrdIOgV2NRNWmwZIXj[YQh[XCxcITvd4l{ NEHBZZUzPDVyNE[4NS=>
CLL MYPBdI9xfG:|aYOgRZN{[Xl? M1TwXFI2|ryP MVWxbC=> NWHWTlV6eGG{dHnhcIx6KGKub3Prd{BOVE5{MkO4MYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN? M4TkUlI1PDZ5NkO0
SGC-7901 MmPLRZBweHSxc3nzJGF{e2G7 MkD0NVDPxE1? MUmyOIg> MlTudJJwdW:2ZYOgeIhmKEOJSVmtbY5pcWKrdHXkJINmdGxiZ4Lve5RpKGmwIGPHR{04QTBzIHPlcIx{ NFLWTWgzPDR3NES4PC=>
k1735 M1;vT2Fxd3C2b4Ppd{BCe3OjeR?= MlPtNlDjiIoQvH2= M1zOUFRp NXTXV25DcW6qaXLpeJPDqFOjbH3vcoVtdGFvaX7keYNm\CCjcH;weI9{cXN? MkPsNlQ1PTFzMU[=
HaCaT  NW[weIE2SXCxcITvd4l{KEG|c3H5 NGHX[HUyODEQvF2= M3\DNlFp NWTifWJR[my3boTzJHVXSi2rbnT1Z4VlKGGyb4D0c5NqeyCrbjDIZWNiXCClZXzsdy=> MmH3NlQ{PTZ7OUe=
podocytes NFHoPIFCeG:ydH;zbZMhSXO|YYm= MmHnNlAx|ryP NVrIcpl3Pmh? MVvpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUA{NDRvRFfF M{G2d|I1OzN5N{e3
 KB NELBWG5CeG:ydH;zbZMhSXO|YYm= MWi1NO69VQ>? NXjobnFyOjSq MUTpcohq[mm2czDMbYNwNUFvaX7keYNm\CClYYPwZZNmNTNiYX7kJHBCWlBiYXP0bZZifGmxbh?= M{C1flI1OzN5NEmy
 HepG2  NIDFZWJCeG:ydH;zbZMhSXO|YYm= M3jLe|Ex|ryP MlXXNlRp MljKdoVlfWOnczD2bY1mdnSrbjDjcIVifmGpZTDjZZV{\WRiYomgUHBU NYnNOWs2OjR|MkW4NVY>
fetal rat lung fibroblasts  NYHqd2t{U2mwYYPlJGF{e2G7 MlrCPFDPxE4EoB?= NEK0e2wycA>? NXzDZpVJcW6qaXLpeJMhS2G|cHHz[U0{KGGldHn2bZR6yqB? MlfPNlQ{OTRzM{W=
PDL fibroblasts M1:1[GtqdmG|ZTDBd5NigQ>? NXHsNI5TQDEQvF5CpC=> MmLUNYg> M2XTbolvcGmkaYTzJGNie3Cjc3WtN{Bi[3Srdnn0feKh MlvONlQ{OTRzM{W=
MB49 NEiySI5CeG:ydH;zbZMhSXO|YYm= NEj6fJEzOM7:TR?= NInMWosycA>? MorkdoV3\XK|ZYOgR20ucW6mdXPl[EBk\WyuIHTlZZRp MWmyOFI5OjR|Mx?=
5637 MUnBdI9xfG:|aYOgRZN{[Xl? NXTLe403OjEQvF2= NI\aUZYycA>? M3u0[ZJmfmW{c3XzJGNONWmwZIXj[YQh[2WubDDk[YF1cA>? NF;WN4IzPDJ6MkSzNy=>
A549  NWTYd4dbSXCxcITvd4l{KEG|c3H5 M33uTVExOM7:TR?= NID0dYY1QGh? NIq2XGd{fXCycnXzd4V{KHSqZTDhdI9xfG:|aYOgZ4F2e2WmIHL5JJBqeGW{aX7lxsA> Mk\BNlQzPzJ{MEG=
MCC-2 MVTBdI9xfG:|aYOgRZN{[Xl? NYX3b|M2OjBizszN M1TKfVZp M4rWe2ROW09? NFTKUFljdG:la4OgbY5lfWOnZDDifUB{fGG3cn;zdI9zcW6nIHHwc5B1d3OrczDj[YxtKGSnYYTo NVP4[JZMOjR{NkK2OVg>
ADF M1fIOmFxd3C2b4Ppd{BCe3OjeR?= MYe0NO69VQ>? M3LnbFZp NIC2bWdqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=> M376WVI1OjJ6MkOy
 U373  Mn\HRZBweHSxc3nzJGF{e2G7 M1\vXFQx|ryP MnfDOog> NFOwbm1qdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=> MmLVNlQzOjh{M{K=
RKO-HIPK2i NGXQe2NCeG:ydH;zbZMhSXO|YYm= NXjkeXQ1PDEQvF2= MkHLOog> MWTpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBkcGWvb4To[ZJieHlicHz1d{BbdkOuMh?= MmH3NlQzOjh{M{K=
HEC-1B NVnPRYpXSXCxcITvd4l{KEG|c3H5 MUWyNO69VQ>? NHf5NYIycA>? MW\y[YR2[2W|IGTQMYlv\HWlZXSgZZBweHSxc3nzxsBk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOR?= NWX2SWszOjR{MUOzOVg>
4T1 MkfXR4VtdCCYaXHibYxqfHliQYPzZZk> M3LWVFIvPS1zMN88US=> NFT4clU1cA>? MUTEUXNQ NYfBN2hZemW|Y4Xld{B1cGViY4n0c5RwgGmlaYT5JI9nKDSWMTDj[YxteyCrbnT1Z4VlKGK7IGPQSHQhcW5iYTDjc45k\W62cnH0bY9vKGSncHXu[IVvfCCvYX7u[ZI> NVj0cmwxOjR{ME[xOlE>
OS  M{fQVWFxd3C2b4Ppd{BCe3OjeR?= MmjyNlDPxE1? MmfyOIg> MoTmbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiY3H1d4VlKGK7IGDEWC=> MljBNlQzODR7M{e=
RPE MlO5RZBweHSxc3nzJGF{e2G7 MnPzNVAx|ryP MVG0PIg> NF7mTZVx[XK2aXHscJkhcW6qaXLpeJMhfGinIHPhcJBicW5vMTDhcoQhNTJiYXP0bZZifGmxbjDhd{B4\WyuIHHzJJRp\SClYYPwZZNmKGGldHn2ZZRqd25? MUeyOFIxOjB3Mh?=
UD29a NFO4OZNCeG:ydH;zbZMhSXO|YYm= NWHJOXZ4PTEQvF2= NX\vS5RNOjSq NGjIOWpqdmirYnn0d{B1cGViY3XscEBl\WG2aDDjZZV{\WRiYomgUnVVOw>? MYGyOFE6ODV5NB?=
SH-SY5Y  Mme2RZBweHSxc3nzJGF{e2G7 MWqxNO69VQ>? MkC0NlRp MoLyZZR1\W63YYTld{Bk[XOyYYPlJIFkfGm4YYTpc44h[W6mIHPlcIwh\GWjdHigbY5lfWOnZDDifUBJVkVvMlTH MkfDNlQyPDV2NkO=
HeLa  M3TFU2Fxd3C2b4Ppd{BCe3OjeR?= NHrGSZIyOC9{MN88US=> NV75SWZqOjSq M2TwdolvcGmkaYTzJJRp\SCjY4Tpeol1gSCxZjD0bIUhdWGsb4LpeJkhd2ZidHjlJI1mdWKncoOgc4YhfGinIHPhd5Bie2VvZnHtbYx6 NXLLVlNnOjRzM{eyOlY>
SCCVII  MVHBdI9xfG:|aYOgRZN{[Xl? MorRNlXPxE1? MXexbC=> MX3pcohq[mm2czD0bIUh[2WubDDrbYxtcW6pIHHmeIVzKGSjc3H0bY5q[g>? NXvnVHJMOjRzMk[0OlQ>
RAW 264.7 MVPBdI9xfG:|aYOgRZN{[Xl? NX22WG1vOjEQvF2= MVGxPIg> NVLscmpNcW6lcnXhd4V{KEyFMz3JTU/Pui2jY4TpckBz[XSrbzDjc41x[XKnZDD0c{BGS1SYLV3PV{B1emWjdH3lcpQhd26ueR?= M3\RWlI1OTF4N{C3
A549  M17IdGFxd3C2b4Ppd{BCe3OjeR?= Ml\2Nk42|ryP MVGyOIg> NGXkfYll\WO{ZXHz[ZMhd3KrZH;ubY4ucW6mdXPl[EBifXSxcHjh[5kh[XNid3XscEBidmRiTH;zd{Bw\iEQlN-IcUBidHOxIH;jZ5VzemWmIHT1dolv\yCjdYTvdIhi\2mlIIDyc4Nme3N? MnXxNlQyODJ3MkK=
UM-SCC-10A  M2fydGFxd3C2b4Ppd{BCe3OjeR?= NHL5Z282OML3TR?= MmXHNog> M{XLW5Jm\HWlZYOgZZBweHSxc3nzJIlv\HWlZXSgZpkhcGmpaD3kc5NmKGm|b3HsZY51d2yjY4TvcoU> M2H5cFI1ODl6N{Wz
BGC-823 NF3YXFFCeG:ydH;zbZMhSXO|YYm= M4LINFExKM7:TR?= NVfKXmRZOjSq M2Kxd5Jm\HWlZYOgeIV1emGwZILpcoUucW6mdXPl[EBieG:ydH;zbZPDqA>? MV[yOFA6QDVzMR?=
Nalm-6  MlfURZBweHSxc3nzJGF{e2G7 MV:yNO69VQ>? NXzCO4p6PGh? NHrEcYlqdmirYnn0d{Bk[XOyYYPlMVgh[W6mIHPhd5Bie2VvMzDhZ5RqfmG2aX;uJIFv\CCSQWLQMVEh[2ynYY\h[4U> NFS4cIEzPDB|OUm2Oy=>
KHOS  NGfKOHRCeG:ydH;zbZMhSXO|YYm= MYC0NO69VQ>? MVqyOIg> NFfaUW1jdG:la4OgeIhmKGmwY4LlZZNm\CClbHXheoFo\SCxZjDjZZNx[XOnLUOgZY5lKFCDUmCgbY5lfWOnZDDifUBDSk2GM9Mg MX2yOFAzPTN4MR?=
G292 M3nO[GFxd3C2b4Ppd{BCe3OjeR?= M3nsclQx|ryP NU\XcnlHOjSq M2HROoJtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC= Mli4NlQxOjV|NkG=
MG-63 Moi2RZBweHSxc3nzJGF{e2G7 MYO0NO69VQ>? NGfyOpMzPGh? NVm3e2Fy[myxY3vzJJRp\SCrbnPy[YF{\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIFv\CCSQWLQJIlv\HWlZXSgZpkhSkKPRERCpC=> NYnCSlZUOjRyMkWzOlE>
EBV-transformed B cells NEjUZ|BCeG:ydH;zbZMhSXO|YYm= NX\tXZh5OjEQvF2= M1rzdVJp NVnzSWtuTE2VTx?= NHPhXGdjdG:la4OgZY51cS2FREiwJIFv\CCjboTpMWNFQDZiYX70bYJw\HlvaX7keYNm\CCjcH;weI9{cXN? NGrIepAzPDByOE[yPC=>
IM-9 B MYDBdI9xfG:|aYOgRZN{[Xl? M{HjT|Ix|ryP NEjSVY0zcA>? M2KwOWROW09? MkDtZoxw[2u|IHHueIkuS0R6MDDhcoQh[W62aT3DSFg3KGGwdHnic4R6NWmwZIXj[YQh[XCxcITvd4l{ MYKyOFAxQDZ{OB?=
CNE1 M3fC[mFxd3C2b4Ppd{BCe3OjeR?= MVKyNO69VQ>? M4H3dVQ5cA>? MX7icI9kc3NiTFutRU1qdmS3Y3XkJIFxd3C2b4Ppdy=> MYGyN|k5PTB{OR?=
CNE2 NXHYO2lbSXCxcITvd4l{KEG|c3H5 M{P1bFIx|ryP MorjOFhp NEjGTW1jdG:la4OgUGsuSS2rbnT1Z4VlKGGyb4D0c5Nqew>? MkDrNlM6QDVyMkm=
HL-60 MYPBdI9xfG:|aYOgRZN{[Xl? M4TYSlUxyrWP MoLnNYg> MoLPSG1UVw>? MknIbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhSkFzNEW= NWDm[2x4OjN7NEi3OVE>
L929 MlXYRZBweHSxc3nzJGF{e2G7 NV[yWGhzOS5{NfMAl|XDqM7:TdMg NG\vSmEzPGh? MkO0ZZVodWWwdIOgWG5H|rFvaX7keYNm\CCwZXPyc5B1d3OrczDhcoQh[XW2b4DoZYd6 M2TwW|I{QTRzN{[5
Jurkat M1XVfmNmdGxiVnnhZoltcXS7IFHzd4F6 MVyy{txO NGLvOmY1cA>? NHnNNGJz\X[ncoPld{Boem:5dHigbY5pcWKrdHnvckBidmRizsKtZ4F1\W6rbjDk[YNz\WG|ZTDifUBJWy2DU1G= MnTGNlM5QTZyNkG=
RAW264.7  M1zYZmFxd3C2b4Ppd{BCe3OjeR?= MlPENVAh|ryP MofQNlRp M3nsTIRm[3KnYYPld{B1cGViYYDvdJRwe2m|IHnu[JVk\WRiYomgS2E> M3vxPVI{QDJyMkCz
A431  MlvrT4lv[XOnIFHzd4F6 MnfoOFDPxE1? MnPSNog> MXjicI9kc3NiZnnz[ZRqdi2rbnT1Z4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2W|IHHu[EBRSVKS MX:yN|gxODB3OB?=
Jurkat NFHnbnBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MY[yOU0yODEQvF2= MUS2bC=> NFXoR5JqdmirYnn0d{B7NU[DLVPNT{1qdmS3Y3XkJINmdGxiZHXheIg> M{W3bVI{QTN|NUOy
COS-7  M2i1[2Z2dmO2aX;uJGF{e2G7 NXrFZpVNPTEEtV2= NHz5b4ozPGh? NFO0PFdi\m[nY4TzJJRp\SCycn;j[ZN{cW6pIH;mJGFVVjG|IIfpeIgheG:ueWGgeJJi[3S| MmDjNlM6OzN{MEi=
CAL27 M2nLT2Fxd3C2b4Ppd{BCe3OjeR?= MVixNEDPxE1? M2L5fFJp MVfzeZBxemW|c3XzJGN2ei2QUIOtdoVlfWOnZDD2bYFjcWyrdImgZpkhfXBidH:gPVAm NXz3ToRGOjN7MUezPVY>
THP-1  MYDBdI9xfG:|aYOgRZN{[Xl? MkXzNVAuPTEQvF2= NEfBfXozcA>? MXHpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUB1emmydH;sbYRm MlfMNlM6ODB{OUm=
K562 NF;rfnpCeG:ydH;zbZMhSXO|YYm= MmLLNlDPxE1? M3OwPFQ5cA>? M2Hmb4lvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KDRvTWW= NGXxS4QzOzh5NkiyOi=>
HL-60 M{jWTWFxd3C2b4Ppd{BCe3OjeR?= NYHEPI04OTByzszN Mk\HNlRp MlS3bY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[WKrZYThcoUh\Gm2ZYLw[Y5me8Li NF3rdoIzOzh4NUe3PC=>
HeLa  NWnZOoR3SXCxcITvd4l{KEG|c3H5 M2nkc|Ix|ryP NVfXWZpKOmh? M37EdYlvcGmkaYTzJGROVVBiaX7keYNm\CCjcH;weI9{cXN? NH3DN|AzOzh4M{m2Oi=>
U251 NXvMS|h4SXCxcITvd4l{KEG|c3H5 NED5T3MzOM7:TR?= Mn\ENlRp MUPpcohq[mm2czDjZZN1cWOrbjDpcoR2[2WmIFeyM20heGijc3WgZZJz\XO2IHHu[EBieG:ydH;zbZM> NGfvOpMzOzhzNkixOi=>
HL-60 NFvWNWxCeG:ydH;zbZMhSXO|YYm= M3HjdVUxyrWP NEH2T3o1cA>? M4DONoJtd2OtczD0bIUh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|LDCtPUwh[W6mIGDBVnAhcW6mdXPl[EBjgSB4cx?= MmfVNlM5ODR5ME[=
Ec-109 MX\BdI9xfG:|aYOgRZN{[Xl? MYmxNEDPxE1? NEjDTHU1QGh? MX7y[ZBz\XO|ZYOgVGUudWWmaXH0[YQhTWNvMUC5JINmdGxiYYDvdJRwe2m| NHXZWHozOzd6Mk[0NS=>
RKO MkPZR4VtdCCYaXHibYxqfHliQYPzZZk> MWOxNEDPxE1? MVeyOIg> NXq2UWZ7cW6qaXLpeJMhfGinIHTlZ5Jm[XOnIH;mJINmdGxidnnhZoltcXS7IHPheZNm\CCkeTDERWI> NVHxcYdIOjN5NUiwOlQ>
T98G M2KyXmNmdGxiVnnhZoltcXS7IFHzd4F6 MV[xMVExOM7:TR?= MX:yOIg> NW\CRY1[cW2ycn;2[ZMh[2WubDD2bYFjcWyrdImgZ491emWjdH3lcpQhf2m2aDDUVy=> NWXGepVUOjN5NkmyO|U>
Jurkat MlnqR4VtdCCYaXHibYxqfHliQYPzZZk> NW\aNW43OTByLUKwNO69VQ>? NGnVZoMzPGh? NEfuUHJqdmirYnn0d{BJ[UF2IHnu[JVk\XNiYYDvdJRwe2m|IHTldIVv\GWwdDDv[kBkd26lZX70doF1cW:wwrC= NHLOS44zOzd|MkS4NS=>
Molt-3  MmraRZBweHSxc3nzJGF{e2G7 NFnUSm42OM7:TR?= MY[ybC=> MVry[YR2[2W|IH3lcIF1d26rbj3pcoR2[2WmIHHwc5B1d3Orcx?= MYOyN|czPTBzMx?=
hMSC12 MULBdI9xfG:|aYOgRZN{[Xl? M3TkWVExOM7:TR?= M3G5blRl NFnJRZpqdmirYnn0d{Bwe3Snb3flcolkKGO3bIT1doUucW6mdXPl[EBk\WyuIHTlZZRpKGGwZDDjZYxkcW[rY3H0bY9v Mn;2NlM3PTd6MkK=
HM7  NEn3UWpCeG:ydH;zbZMhSXO|YYm= M4i0U|Ix|ryPwrC= MkjRNYg> MWXicI9kc3NiYYDpZ5Vt[XKnbjDBJIFk\XSjdHWtbY5lfWOnZDDjZZNx[XOnLUOgZYN1cX[jdHnvckBidmRiUFHSVEBkdGWjdnHn[S=> MYqyN|U5OzRzMh?=
Hep-2  MlruRZBweHSxc3nzJGF{e2G7 NXXWRZYxOjEQvF5CpC=> NVzvNng1OjSq M4rYWGROW09? MU\hcIxmfmmjdHXzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSCrbnT1Z4VlKGK7IIPpcIljcW6rbh?= MnLENlM2QDByM{K=
HSCs NHfOcpZCeG:ydH;zbZMhSXO|YYm= MXS1NO69VQ>? MWeyOIg> NHvnb3hFVVOR MoPybY5pcWKrdIOgcoltd3SrbnniMYlv\HWlZXSgSG5CKGSjbXHn[UBqdmSrY3H0[YQh[nliUFHSVEBkdGWjdnHn[S=> NWW4WJMyOjN2OUm4O|Q>
HL-60  NFuwNGJEgXSxdH;4bYNqfHliQYPzZZk> NHjRbVIzOM7:TdMg NIi4UVYzPGh? NVuwelA5emWmdXPld{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDFdpk2 MVeyN|Q6PDR6MB?=
HA MoDoRZBweHSxc3nzJGF{e2G7 MV[1NO69VQ>? M1:3elI1cA>? NVvHeVZQe3WycILld5NmeyC2aHWgZ4xm[X[jZ3Wgc4YhWEGUUDDhcoQh[2G|cHHz[U0{NCBvNzygZY5lKC17IHnu[JVk\WRiYomgZo9zfGW8b33pZk9USUiD NYPyNod4OjN2N{W5OVY>
C666-1 M4nSS2Fxd3C2b4Ppd{BCe3OjeR?= NUPSVYdNPTEQvF2= NVfROoxMOjSq NGDJfYZ{fXCycnXzd4V{KHSqZTDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMtKC15LDDhcoQhNTliaX7keYNm\CCkeTDic5J1\XqxbXniM3NCUEF? NHzqfIszOzR5NUm1Oi=>
Hepa1-6 NFTQNIlCeG:ydH;zbZMhSXO|YYm= M3XJeVUx|ryP M3jZVFJp MYHpcohq[mm2czDjeZJkfW2rbjDhcoQhemW|dnXyZZRzd2xvaX7keYNm\CCjcH;weI9{cXN? MUeyN|Q1Pjd3Mx?=
PLC/PRF/5c M1r5PWFxd3C2b4Ppd{BCe3OjeR?= NVvLRoFzPTEQvF2= NWTvSnZMOWh? NXvxV3NieHKndnXueJMh[XCxcITvd4l{KHS{aXfn[ZJm\CCkeTDDTW4> MkPCNlM1Ozh6MkS=
HCT116 MlzCRZBweHSxc3nzJGF{e2G7 M3nzc|ExOM7:TR?= NHG3R4UyNjWq MUfpcohq[mm2czDPd{1qdmS3Y3XkJINmdGxiZHXheIg> NYrLfG9sOjN5NESzOVM>
HCEC NIT0O2pHfW6ldHnvckBCe3OjeR?= NIDKTVM2OM7:TR?= MoXiO|Jp MmfnSG1UVw>? NVzaTYxremW|dH;y[ZMhd2ZidHjlJI5wem2jbDDIR2VEKHCqZX7veJlx\Q>? NYLDeYdkOjN5NEKwNVE>
Primary rat cerebral cortical neurons NUPJeZhjSXCxcITvd4l{KEG|c3H5 NXTuemo5OTByzszN M1u1OVFp NEfYVoRxemW4ZX70d{BE\C2rbnT1Z4VlKGGyb4D0c5NqeyCjbnSgZ4VtdCCmZXH0bC=> MUOyN|c1OTNzNx?=
MDA-MB-231  MWTBdI9xfG:|aYOgRZN{[Xl? NWLwT2NVOjYQvF2= MXmyOIg> M162NYFjem:pYYTld{BkgXSxdH;4bYNqfHliYX7kJINt\WG4YXflJI9nKGOjc4Dhd4UuOyCjbnSgVGFTWCCrbnT1Z4VlKGK7IGLnNy=> M{nsZVI2OzN5NUS0
NLRP3-Tet-on-MC/9  M1Tjc2Fxd3C2b4Ppd{BCe3OjeR?= MWOxNE01OM7:TR?= NFTldYEyOmh? NXTvOXFy[XS2ZX71ZZRmeyC2aHWgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhS0GSUz3hd5Nw[2mjdHXkJG5NWlB|IH31eIFvfHNiaX6geIhmKFSndD3vckB{gXO2ZX2= NWjsSGNVOjN5MEOzPFk>
KNS42  M1\5VGFxd3C2b4Ppd{BCe3OjeR?= NWPmNXhWPTEQvF2= NFPienUycA>? MWLy[YR2[2W|IHPlcIwh\GWjdHigZY5lKGOxbYDs[ZRmdHliYXLvcIl{cGWmIHPhd5Bie2ViMz:3JIFkfGm4aYT5JIlvKHKnc4DvcpNmKHSxIFHCWE0zPjNxMlTHM41mfG[xcn3pckBkd22kaX7heIlwdg>? MYWyN|Y6OTF2NR?=
MCF-7  NXTWXXZqSXCxcITvd4l{KEG|c3H5 M2TVVlIx|ryPwrC= MnnkO|Jp MVXpcohq[mm2czDldZVwdC1iYX7kJFQuV0iWLX3l[IlifGWmIHHwc5B1d3Orcx?= M3XJ[lI{Pjd3NkSz
hCMEC/D3  NFXmVplCeG:ydH;zbZMhSXO|YYm= NH3s[lIzPc7:TR?= MnP4O|Jp M1\3R5Jm\HWlZYOgUJR5SSCrbnT1Z4VlKGGyb4D0c5Nqew>? MlH2NlM3PjVzOUi=
Jurkat NY[5e4ExSXCxcITvd4l{KEG|c3H5 MmrDNVIvPS13MN88US=> M1\SXVFp MV\kc5NmKGSncHXu[IVvfGy7IIP1dJBz\XO|ZYOgV3BJNWmwZIXj[YQhWGG{LUSgZ4xm[X[jZ3WsJHBCWlBiY3zlZZZi\2VuIFTORUBnemGpbXXueIF1cW:wLDDhcoQhdG:|czDv[kB3cWGkaXzpeJk> NHv5PJozOzR2Mkm3Oi=>
CNE-1 NFPQbXNCeG:ydH;zbZMhSXO|YYm= MnXRNlDPxE4EoB?= MYqyOIg> M2TUe4lvcGmkaYTzJHJCTDByMT3pcoR2[2WmIHPlcIwh\GWjdHi= M{XJUFI{PDJ4OEWw
HONE-1 MY\BdI9xfG:|aYOgRZN{[Xl? NITYR|EzOM7:TdMg MV:yOIg> MkDwbY5pcWKrdIOgVmFFODBzLXnu[JVk\WRiY3XscEBl\WG2aB?= NEiwOHgzOzR{Nki1NC=>
astrocytes cell M{jIVmFxd3C2b4Ppd{BCe3OjeR?= NXvCPGVrPDEQvF2= M1XXfFZp NYLNZnlzemWmdXPld{Bm[XKueTDhdI9xfG:|aYOgbY5lfWOnZDDifUB{fGG3cn;zdI9zcW6n MoLtNlM1OTF5N{i=
U-937 NHHCXm9CeG:ydH;zbZMhSXO|YYm= Mom5NVDPxE1? NWrESoFkOzCvaX6= NHn5Z|BxemW4ZX70d{BVVkZvaX7keYNm\CCwZXPyc5B1d3Orcx?= NYLCWlZROjN2MUC3OFg>
MDA-MB-231 MmTmRZBweHSxc3nzJGF{e2G7 MmniNVAx|ryP Ml;qNYg> M1W0[4lvcGmkaYTzJJNmdnOrdHn6ZZRqd25idH:gWHJCUUxidYDvckBOXESKIHTve44uemWpdXzheIlwdg>? MmrJNlM1ODh2Mkm=
HeLa  M2n0V2Fxd3C2b4Ppd{BCe3OjeR?= Ml;PNVAx|ryP NEnXWY4zcA>? NXK0VlRy[myxY3vzJGpTWy1zNTDJcoR2[2W|IFHwc5B1d3SrYzDD[YxtKESnYYTo M{P6V|I{OzR2MES1
Ec109 NUjJcJUzSXCxcITvd4l{KEG|c3H5 NX7UeYpEOTEQvF2= MmDwOog> MUDicI9kc3NiYYDvdJRwfGmlIHPvcYJqdmG2aX;uJI9nKFSjdD3TcYFkVjdiYX7kJJJi\GmjdHnvci=> NHPmSoUzOzN|OEW2PC=>
H460  M4XL[2Fxd3C2b4Ppd{BCe3OjeR?= M4LwR|Ex|ryP M13Gb|Zp NX[1WnpG[myxY3vzJIFxd3C2b4TpZ{Bkd22kaX7heIlwdiCxZjDUZZQuW22jY163JIFv\CC{YXTpZZRqd25? MlfmNlM{Ozh3Nki=
HeLa  MnTJRZBweHSxc3nzJGF{e2G7 M3;rRlUx|ryP M{T6RVEvPWh? MUnhZpJw\2G2ZYRCpGNpdGGveXTpZU1qdmS3Y3XkJIFxd3C2b4Ppdy=> NYPxV|l4OjN|MEO4NFQ>
SK-HEP1 NUf2SXNKSXCxcITvd4l{KEG|c3H5 Mny0NVAx|ryP NVLiR2VLOWh? Mm\MbY5pcWKrdIOgR5JVOSCjY4TpeoF1\WRiY3HzdIF{\S1|LDCtO{whNThuID25MEBidmRicH;sfUhCTFBvcnnic5NmMSCyb3z5cYVz[XOn MlX4NlM{ODJ4NUC=
QGY7701 NIDOVG5CeG:ydH;zbZMhSXO|YYm= NF3tNGYzPc7:TR?= M3LITVEvPWh? NH\4S2ZqdmirYnn0d{Bi[2O3bYXsZZRqd25ib3[gd5VjNUdzIIDoZZNmKGmwZIXj[YQh[nliRF;YJEsheXWncnPleIlv MlnZNlMzPDByNkG=
HepG2 MUnBdI9xfG:|aYOgRZN{[Xl? NY\LOGxqOjEQvF2= MlL4N|BucW5? NUjSWW8zcW6qaXLpeJMhfGinIHXubIFv[2WmIHPlcIwh\GWjdHigZpkh[2:vYnnu[YQhfHKnYYTt[Y51KG:oIHHwbYdmdmmwIHHu[EBVWkGLTB?= MXeyN|IzPDJ|OR?=
U87  MlezRZBweHSxc3nzJGF{e2G7 M4POUFI2|ryP NXjNU2dnOmh? M13qcIRm[3KnYYPld{Bqe2:uaYH1bZJqfGmpZX7pckApUVOOKT3pcoR2[2WmIHHwc5B1d3SrYzDj[YxtKGSnYYToMEBjfXRibn;0JI5m[3KxdHnjJINmdGxiZHXheIg> NInT[2YzOzJ{OU[yOi=>
HSC-2 M1W3TmFxd3C2b4Ppd{BCe3OjeR?= NUHjSHdjOjVxNUFOwG0> M3\RNlFp M{PXeYlvcGmkaYTzJHNPNTN6LXnu[JVk\WRiY4n0c5RwgGmlaYT5 MkftNlMyPTV{NEi=
HSC-4 NGjlZoNCeG:ydH;zbZMhSXO|YYm= M3jmNVI2NzVyzszN M{fWTlFp NX20b2xZcW6qaXLpeJMhW05vM{itbY5lfWOnZDDjfZRwfG:6aXPpeJk> NV7ZfXM4OjNzNUWyOFg>
CL-1 Mm\ZRZBweHSxc3nzJGF{e2G7 NUX5SIxVOjEQvF2= MV[xbC=> NFvyc|NjdG:la4OgU3A1PDliaX7keYNm\CClZXzsJIRm[XSq MWSyN|E{OTd6Mh?=
MEL MVTBdI9xfG:|aYOgRZN{[Xl? M2KzRlIx|ryP MoHpNlRp M1u2N2ROW09? MUnpcZBicXKnczDQNng4NWmwZIXj[YQhVUWOIHPlcIwh[XCxcITvd4l{ MVqyN|AyPDh6Nx?=
Bel-7402  Mn7xR4F{eGG|ZTDBZ5RqfmG2aX;uJGF{e2G7 NX;kdZJlPTEQvF2= NV22VphbOmh? MV\pcohq[mm2czDQR2UucW6mdXPl[EBidm:ra3nz M33HNFI{ODB6N{Sy
Eca-109 MY\BdI9xfG:|aYOgRZN{[Xl? M3v5OFI2|ryP MnzvN|BucW5? NGDZOpVqdmirYnn0d{BDUi2EMUGtbY5lfWOnZDDj[YxtKGSnYYTo M4TPe|I{ODd4OU[3
MEL MnXrRZBweHSxc3nzJGF{e2G7 MXqyNO69VQ>? NUfEWJl4OWh? MXHEUXNQ MmX1bY1x[Wm{ZYOgVFJZPy2rbnT1Z4VlKE2HTDDj[YxtKGGyb4D0c5Nqew>? NF[2dokzOzBzNEi4Oy=>
Bel-7402  M2jPRWFxd3C2b4Ppd{BCe3OjeR?= M37sZ|Ux|ryP M4\rb|Jp NWLGfopscW6qaXLpeJMhWEOHLXnu[JVk\WRiYX7vbYtqew>? M4[3UVI{ODB6N{Sy
L929 NY\LPY56TnWwY4Tpc44hSXO|YYm= MWWyMlXPxE1? NXTlTXVzOWh? M1viWolv[3KnYYPld{BTUVBzIHX4dJJme3Orb36gZY5lKGW6YXPldoJifGWmIGTOSu6yNWmwZIXj[YQhdWm2b3Poc45lemmjbDDkfZNnfW6ldHnvckBidmRiUl;TJJBzd2S3Y4Tpc44> MUSyN|AxODVzOB?=
RCC  MX3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnP3NVAx|ryP MXOyOIg> MWHy[YNwfmW{ZYOgeIhmKH[rYXLpcIl1gSCxZjDj[YxteyCneIDvd4VlKHSxIEG1[E1RT0p{ MXiyNlk6OTR7NB?=
NB2a/d1 NF3OV5RCeG:ydH;zbZMhSXO|YYm= M{DucVExOM7:TR?= NH3ITXU4Omh? MUjheJRmdnWjdHXzJJN1[XW{b4Pwc5JqdmVvaX7keYNm\CClYYPwZZNmKGGldHn2bZR6NCCSQWLQMEBidmRidHH1JINt\WG4YXfl MkPINlI6QDh3NEG=
T cell MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPPZ|FrOjVvMUCw{txO MViyOIg> MUnkc5NmNWSncHXu[IVvfGy7IHnubIljcXSnZDDUJINmdGxicILvcIln\XKjdHnvckBu\WSrYYTl[EB1cHKxdXfoJJRp\SClbz3zeIlufWyjdHnvckB4cXSqIHHueIkuS0R|IHHu[EBidnSrLVPENlg> MYmyNlk5OjV|OB?=
K562 MVjBdI9xfG:|aYOgRZN{[Xl? MXyxNFDPxE1? Mk\6NYg> MnPXZoxw[2u|IFHico9j[X[rc3P1ceKhTi2rbnT1Z4VlKGGyb4D0c5Nqew>? NXHFXVB6OjJ7N{KzO|I>
Jurkat  MoPTRZBweHSxc3nzJGF{e2G7 MmPWOFDPxE1? M2PBRVFp MmTIZYJwdGm|aHXzJGZie0xvaX7keYNm\CClYYPwZZNmKGGldHn2ZZRqd25iYX7kJINmdGxiZHXheIg> MWqyNlk1Ojd|OB?=
BGC-823 NEe5UJlCeG:ydH;zbZMhSXO|YYm= M3WxOVExOM7:TR?= M{DPUlFp M3iwcZBienSrYXzsfUBz\XOldXXzJINmdGy|IHHnZYlve3RiZHHtZYdmKG:oIHThbYR7\Wmw NHXEe2EzOjl{NkW0OS=>
Hep3B M{PMUGFxd3C2b4Ppd{BCe3OjeR?= M4raNVUx|ryP MU[xbC=> NHLIVmRjdG:la4OgZZBweHSxc3nzJIlv\HWlZXSgZpkhUEWJQ4O= M2Hh[FIzQTJ|MUW0
LLC-PK1 NFXnSVlCeG:ydH;zbZMhSXO|YYm= NVXt[GNtOjEQvF2= NInO[4kycA>? Mn7BdJJmfmWwdIOgZ4l{eGyjdHnuMYlv\HWlZXSg[IVoemGmYYTpc44hd2ZiQYTnOUwh[mWlbHnuMVEtKGGwZDDBeIcyOiCycn;0[Ylvew>? MkLxNlI5QTZyM{e=
A549 MXPBdI9xfG:|aYOgRZN{[Xl? NUPyW5FpPTEQvF2= Mny0NYg> NEfZ[lRjdG:la4OgeIhmKEKDST3pcoR2[2WmIHHwc5B1d3Orc9Mg NF;XWXozOjh6N{KxOS=>
SGC-7901  MVTBdI9xfG:|aYOgRZN{[Xl? MV6xNO69VQ>? Mm\yNlRp MmG0bY5pcWKrdIOg{tIt|rJvZHnt[ZRpgWyjY4L5cJNpcWuxbnnuMYlv\HWlZXSgZZBweHSxc3nzxsA> NGTYWm8zOjh2OEW5Oy=>
DM6 NGXoZlVCeG:ydH;zbZMhSXO|YYm= M3raV|ExOM7:TR?= NYHMXGttPzKq MUTicI9kc3NiYn;0bEBGOkZvMTDhcoQhTTKIdIKtcYVlcWG2ZXSgZ5l1d3SxeHnjbZR6 NILhPWQzOjh{NUOyPC=>
MCF-7, MDA-MB-468, Caco-2 NWfBRVdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXK1NO69VQ>? MoHROFhp Mnf5bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnubIljcXSrb36gbY5lfWOnZDDifUB{[XCxbnnu NIPmbZQzOjhyMEm2PC=>
A2750  MkLBRZBweHSxc3nzJGF{e2G7 NYT5bohmOjEQvF2= MojQNog> NXHHVFlzTE2VTx?= MYricI9kc3NiY3HzdIF{\SClbHXheoFo\SCmdYLpcochcGWuZX7hcIlvKHS{ZXH0cYVvfCCjbnSgdoVlfWOnczDheZRweGijZ3njJINmdGxiZHXheIg> NEjRUXIzOjd6NEO2Ny=>
U87  MlftRZBweHSxc3nzJGF{e2G7 NF\BVYczOM7:TR?= MmLSNlRp MmDWdoVlfWOnczD0bIUh[XCxcITvd4l{KHKjdHWgbY5lfWOnZDDifUBRVEGE M3rFUVIzPzd6N{iw
HT1080 NHPp[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{n2UVUx|ryP M370fVdl NYTTc41zcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[2G3c3XkJIJ6KGOxbXLpcoVlKHS{ZXH0cYVvfCCxZjDER2Eh[W6mIF;NVC=> MmLqNlI4PDB7OES=
A549  MYfBdI9xfG:|aYOgRZN{[Xl? MXy1NO69VQ>? MX[ybC=> M{LoZpBienSrYXzsfUBl\WO{ZXHz[ZMhe2:maYXtJJNmdGWwaYTlMYlv\HWlZXSgZZBweHSxc3nz MlfvNlI4OjF6MES=
Primary OPC NXL1XIk2SXCxcITvd4l{KEG|c3H5 NXfaU|hROc7:TR?= MWi2bE8zPGh? NUjCSXh7emWmdXPld{B1cGVicHXyZ4VvfGGpZTDv[kBk\WyuczDpckBm[XKueT2gZY5lKGyjdHWtZZBweHSxc3nzM45m[3Kxc3nz MV:yNlcxPzN6NR?=
PMNs MnXzRZBweHSxc3nzJGF{e2G7 MkLPOFDPxE1? MUi2bC=> NXPtZWJ3TE2VTx?= MWLy[ZZmenOnZDD0bIUh[W2xdX70JI9nKGOuZXH2[YQh[2G|cHHz[U0{KHSxIH7lZZIhfmWqaXPs[UBt\X[nbIO= NH7pSYgzOjZ7MkW3Oy=>
A549  M{LN[WFxd3C2b4Ppd{BCe3OjeR?= NWfmSGFKPTEQvF2= NWfEU2JwOWh? M3\QepBz\X[nboTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEKjb3j1c5Nq\GViSR?= NVXrbGt2OjJ4OEe2N|U>
AGS MWTBdI9xfG:|aYOgRZN{[Xl? NYrVR4w{OjEQvF2= MmXINVJp M3fiUolvcGmkaYTzJJRp\SCjY4TpeoF1cW:wIH;mJJBzdy2lYYPwZZNmNTNiaX6gdoV{eG:wc3WgeI8hfGinIFX0U2FkKG[{YXP0bY9v NGW4VmozOjZ6N{O5PC=>
shC9  MYnBdI9xfG:|aYOgRZN{[Xl? Mn[5NVDPxE1? NUfRdVFCOT[q NH;LXmhjdHWwdIOgV2hJKGW6cILld5Nqd25iaX6gd4hEQSClZXzsd{BmgHCxc3XkJJRwKGWrdHjldkBRSSCxcjDMVGM> NHnRPGQzOjZ2MUC5OC=>
primary MEFs NUnzNYEyTnWwY4Tpc44hSXO|YYm= MXKxNog> NHHQPZfDqGmwY4LlZZNmeyCndH;wc5Nq\GVvaX7keYNm\CCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJIRmeG:uYYLpfoF1cW:w NUWyeppLOjJ4MUO3Olc>
3T9 MEFs MXHGeY5kfGmxbjDBd5NigQ>? Mm\SNVZp MnHqbY5kemWjc3XzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGGodHXyJIV1d3Cxc3nk[U11emWjdH3lcpQ> MlzhNlI3OTN5Nke=
3T9 MEFs NGfieZFHfW6ldHnvckBCe3OjeR?= NHT5bpEyQGh? MVX1dJJm\3WuYYTld{Bqdmm2aXH0c5Ih[2G|cHHz[U06KGK3dDDkc5dvemWpdXzheIV{KGWoZnXjeI9zKGOjc4Dhd4V{KGGodHXyJIV1d3Cxc3nk[UB1emWjdH3lcpQ> MlnSNlI3OTN5Nke=
MDA-MB-231  M2TOUGFxd3C2b4Ppd{BCe3OjeR?= M3X4fFIx|ryP NVPsPXd1PGR? M2rU[ZJm\HWlZYOgeIhmKGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhdWW2Zn;ycYlvKHS{ZXH0cYVvfCC5YYOgd4lodmmoaXPhcpRtgQ>? NWnpVFJTOjJ3OUO0OFE>
C6  NIXhTGxCeG:ydH;zbZMhSXO|YYm= NUnscJJmOTEQvF2= MkDkNlRp NFvmdFljdG:la4OgeIhmKHO3cIDy[ZN{cX[nIHXm[oVkfCCxZjD0bIUheGWydHnk[UBwdiC4aXHibYxqfHl? MonzNlI2QDh7OEC=
HL-60  NELuVXhCeG:ydH;zbZMhSXO|YYm= NULlXXpXOTByzszN MX:yOIg> NXzZO5V{cW6qaXLpeJMhfGinIHPlcIwh[XCxcITvd4l{KHOnbHXjeIVlKChtKT3t[Y51cHmuIN8yMUgy6obUNjmt[IlodHWlb4D5doFvd3OrZHZCpFU> MVuyNlU1PjZ4OR?=
HL-60 Mo\ERZBweHSxc3nzJGF{e2G7 M13ieFExNThyzszN M1zO[|Rp MV7pcohq[mm2czDUS2hSNWmwZIXj[YQh[2WubDDhdI9xfG:|aYRCpC=> NXnHTml{OjJ3MkOyNlk>
BCC M{\lNmFxd3C2b4Ppd{BCe3OjeR?= NFPRcII2OM7:TR?= MmrWNYg> NEjpN|BqdmirYnn0d{BFSVSVLX3l[IlifGWmIHfyc5d1cCCrbnjpZol1cW:w Mom4NlI2OTl2M{[=
RAW 264.7 NHLxV3VCeG:ydH;zbZMhSXO|YYm= NVTNPYI4PTBxMUCw{txO NVHXNFhROWh? NFvye41kd26lZX70doF1cW:wLXTldIVv\GWwdDDpcohq[mm2czDEU24ucW6mdXPl[EBzWk6DIHPs[YF3[Wen NVjBRolIOjJ2OUG0NlY>
K562 MlL6RZBweHSxc3nzJGF{e2G7 NWL2bGk{OjYQvF2= M3zIZlJp M{C1dZBz\X[nboTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOxLYTy[YF1dWWwdDD3bZRpKGGvdYLlcpNqdiCJIHHu[EBVWkGLTB?= MUWyNlQ5Ozd5Nx?=
SGC-7901 M{LVN2Fxd3C2b4Ppd{BCe3OjeR?= NXLI[W5[OjBizszNxsA> M2PqfVJp NX\JdpdO[XS2ZX71ZZRmeyCKMl:yxsBweiCWTl[g{tEucW6mdXPl[EBk\WyuIHHwc5B1d3OrczDhd{B4\WyuIHHzJINie3Cjc3WtN{Bi[3Srdnn0feKh NUDPWJdOOjJ2N{G1PFk>
PC3 M2nu[WFxd3C2b4Ppd{BCe3OjeR?= Mm\jNVDPxE1? M{\aWFRp MYfjc5VvfGW{czDmcIF3d2OxeHnkMYlv\HWlZXSgZ4F{eGG|ZT3y[YxifGWmIHHwc5B1d3Orcx?= NH3SOWozOjR5MUm3OC=>
SMMC-7721 MX3BdI9xfG:|aYOgRZN{[Xl? NXS5eFZSPTEQvF2= MkDvOFhp MnzkZZR1\W63YYTld{BwXFJvaX7keYNm\CCjcH;weI9{cXN? MVmyNlQ3PTh|Mx?=
HeLa  MkH4RZBweHSxc3nzJGF{e2G7 NUfxTlkxPTEEoN88US=> MUW0M|hp MoiybY5pcWKrdIOgV3RUNWmwZIXj[YQhdGG2ZT3wbIF{\SCjcH;weI91cWNiZY\lcpR{ MWmyNlQ3ODVyNB?=
HeLa  MVHBdI9xfG:|aYOgRZN{[Xl? MnLCOVDDqM7:TR?= MkewNYg> M1KwV5N2eHC{ZYPz[ZMhfGinIF\SRXAucW6mdXPl[EBi[2O3bYXsZZRqd25ib3[gZY5v\XirbjDWJJBwe2m2aY\lJINmdGy| M2r5OlIzPDR7NESw
T47D  NVPZRmhrSXCxcITvd4l{KEG|c3H5 NUj3R|hiOTByzszN MnTJNYg> MWficI9kc3NidHjlJIdmdmW{YYTpc44hd2ZiRT3jZYQwS1SIMjDifUBUXFN? MXWyNlQxOTF4OB?=
HeLa  NFj5UnlCeG:ydH;zbZMhSXO|YYm= NV33XmdMOzEQvF2= NXPxXGc4PGh? MWhCpIlv[3KnYYPld{B1cGViZ3Xu[ZJidCClZXzsJJZq[WKrbHn0fUA1QCCqIHHmeIVzKHCqb4Tv[Jlv[W2rYzD0doVifG2nboVCpC=> NYe5VYtTOjJ|OUSyOFg>
HCC M4HzbGFxd3C2b4Ppd{BCe3OjeR?= NHTHfFczOCEQvF5CpC=> MUWybC=> M4nHW4F1fGWwdXH0[ZMhfGinIFTIRUBqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiUFHSVC=> NWKzN2s4OjJ|NEK3N|I>
mESCs NWHPeFJ4SXCxcITvd4l{KEG|c3H5 MnixNk42|ryP NUjBU5d1Omh? NHPPW3dqdmirYnn0d{B1cGViTnHGMY1m\GmjdHXkJINie3Cjc3WgZYN1cX[jdHnvci=> MWmyNlI5PTJ5NB?=
EMT-6  Ml3OR5l1d3SxeHnjbZR6KEG|c3H5 NVrNPIh[OTByzszN NFHGWXQycA>? MXLwZZJ1cWGubImgZoxw[2unZDDj[YxtKGSnYYToJIlv\HWlZXSgZpkhe2m{YX3ld4lv\Q>? Mo\MNlIzPTF7MkG=
MCF7 NILGPIRCeG:ydH;zbZMhSXO|YYm= MlntOVDDqM7:TR?= NFHwNGcycA>? M1zCfolvcGmkaYTzJHBCKGGldHn2ZZRm\CClYYPwZZNmNTNuID25MEBidmRicH;sfUhCTFBvcnnic5NmMSCyb3z5cYVz[XOn NH;1c5QzOjJ{M{O0OS=>
K562 NX\ZV2NbSXCxcITvd4l{KEG|c3H5 MYqyNEDPxE4EoB?= NUX5[VJ6PDiq Mly3SG1UVw>? MWLicI9kc3NibHHwZZRqdmmkLXnu[JVk\WRiaX7obYJqfGmxbjDv[kB3cWGkaXzpeJkh[W6mIHHwc5B1d3OrczDpcoR2[3Srb36= NWe5NW84OjJ{MU[xOVg>
Molt4-hyg NUjmdGJnSXCxcITvd4l{KEG|c3H5 MmjGNVDPxE1? NHfYWYExNjWq NY[zNGdw[myxY3vzJIZiem6nc3;sMYlv\HWlZXSgZ4F{eGG|ZT2zMYxqc2ViYXP0bZZqfHl? MViyOlI4PThzMR?=
HeLa NFzR[ZNCeG:ydH;zbZMhSXO|YYm= MX[xNO69VQ>? M3nCZ|AvPWh? MmHVbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhfGinIHPvcYJqdmWmIITy[YF1dWWwdDD3bZRpKGexbXnzbY4hViCjbnSgWHJCUUx? MoTQNlIyPzl4NkG=
Jurkat T NVjDd2tpSXCxcITvd4l{KEG|c3H5 M{jyRVMx|ryP Mn;lNE42cA>? MlfvSG1UVw>? NFLmUFhjdG:la4OgeIhmKHqrcnHtMYlv\HWlZXSgZZBweHSxc3nz MnnMNlIyPTl6OUi=
Neutrophil M16xeGFxd3C2b4Ppd{BCe3OjeR?= M3rqe|Ix|ryP Ml\2NE42cA>? NFvYWHlifHSnboXheIV{KHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeEBw\iCPYWKx NXn6T4xxOjZzOU[4OFQ>
HCT116 MknsRZBweHSxc3nzJGF{e2G7 NV;3XZlFPTEEoN88US=> NIPmVIQzcA>? NG[4UpZz\X[ncoPld{B{gW6ncnfpd5Rq[yCjcH;weI9{cXNiZX\m[YN1eyCxZjDj[Yxm[2:6aXKgZY5lKE6SQz2xOuKh NWLHSGI6OjJzNUm3OVI>
MDA-MB-231  NWPIboc4SXCxcITvd4l{KEG|c3H5 M3exUVIvPS15LkZOwG0> Mn3pNog> NV\2bHU1cW6qaXLpeJMhfGinIHPlcIwh\GWjdHigc4YhVUSDLV3CMVI{OSClZXzsd{BqdmS3Y3XkJIJ6KFOGVDDpckBiKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70JI1idm6nch?= M{fhbVIzOTF3NUK2
LNCaP MYfBdI9xfG:|aYOgRZN{[Xl? MoToOFDPxE1? NUO2fJR4Omh? MV\pcohq[mm2czDieZRmcW5iaX7keYNm\CClZXzsJIFxd3C2b4Ppdy=> MXeyNlEyPDd4NB?=
MB231 M4rCV2Fxd3C2b4Ppd{BCe3OjeR?= MlXoNVAx|ryP NIXEOJUycA>? MnzpSG1UVw>? M2DIfYFjem:pYYTld{B1cGViaX7keYN1cW:wIH;mJINmdGxiZHXheIgh[nliV1XFNUBqdmirYnn0bY9vNCCWUlHJUEB1emWjdH3lcpQtKGGwZDD0bIUh[2:vYnnuZZRqd25? Mn;5NlIyOTJ7NEC=
HCC38  MknLRZBweHSxc3nzJGF{e2G7 NGLsdXMyODEQvF2= M4jaOVFp NV;4cW9pTE2VTx?= MmjMZYJzd2ejdHXzJJRp\SCrbnT1Z5Rqd25ib3[gZ4VtdCCmZXH0bEBjgSCZRVWxJIlvcGmkaYTpc44tKFSUQVnMJJRz\WG2bXXueEwh[W6mIITo[UBkd22kaX7heIlwdg>? NGGwN5gzOjFzMkm0NC=>
MDA-MB231 MofIRZBweHSxc3nzJGF{e2G7 NWn0VnBQPTEEoN88US=> NGjDNIUzPGh? NV;mdIVSTE2VTx?= M1vMWoFjem:pYYTld{BkfXKldX3pck1qdmS3Y3XkJINmdGxiZHXheIg> MnH2NlIyODF|M{W=
LNCaP M4iyNWFxd3C2b4Ppd{BCe3OjeR?= NUTqOIQ6PTEEoN88US=> MmnVNlRp MYLEUXNQ NX3kXIhu[WK{b3fheIV{KGO3cnP1cYlvNWmwZIXj[YQh[2WubDDk[YF1cA>? M17vWVIzOTBzM{O1
HCT116 NFTqeGJCeG:ydH;zbZMhSXO|YYm= M2jtbVUxyqEQvF2= NGf2PZMzPGh? M33wWGROW09? Mkj3ZYJzd2ejdHXzJIN2emO3bXnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MoPZNlIyODF|M{W=
Ishikawa  M{n1[mFxd3C2b4Ppd{BCe3OjeR?= MVqyOe69VQ>? NULtOoYyOjSq NXTwfnB7emWmdXPld{Bk\WyuIHTlZZRpKGGwZDDhdI9xfG:|aYOgbY5lfWOnZDDifUBD[WZiQUG= NV;rblJvOjJyOEi5NVg>
 YD-8  MnywRZBweHSxc3nzJGF{e2G7 MX[xNFDPxE1? MWqxbC=> NH7xUW1qdmirYnn0d{BRVEWRLXnu[JVk\WRiYYDvdJRwe2m| NYX1OVg2OjJyOE[xPFM>
eosinophil  M{LKcGFxd3C2b4Ppd{BCe3OjeR?= MnTWPVDPxE1? NI\4W4szPGh? M4rZcYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KE[jczDhcpRq[m:medMg MojiNlIxPzl|M{S=
L929 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Pw[lIvPc7:TR?= M{C4XVI1cA>? NWLEUGpYcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YheC2yM{igZY5lKE6ILd86RkB1dyCjdXft[Y51KFSQRt8xMYlv\HWlZXSgcoVkem:ydH;zbZMh[W6mIHH1eI9xcGGpeR?= Mn3PNlIxOjdyOUe=
YD-8  MUHBdI9xfG:|aYOgRZN{[Xl? NV\ZOFM4OTByzszN NFrY[mcycA>? MUXicI9kc3NidHjlJGdUNUiFbD3pcoR2[2WmIHHwc5B1d3Orcx?= NFe0UmwzOjB{MEC3PC=>
HBx Mo\mRZBweHSxc3nzJGF{e2G7 NITqcnQzPc7:TR?= NVHNNYFmPDiq NGX4bZBFVVOR NUPuU4ZiemWmdXPl[EBk\WyuIHTlZZRpKGmwZIXj[YQh[nliMz3NRS=> M4fjS|IzODJyMEe4
U937  MUjBdI9xfG:|aYOgRZN{[Xl? NIrlVHU2OMLizszN M3rISVFp MmXibY5pcWKrdIOgTGYucW6mdXPl[EBieG:ydH;zbZPDqA>? NUPPcmZqOjF7OUi3N|E>
HL60 M{PKeGFxd3C2b4Ppd{BCe3OjeR?= NGqxW4o1OM7:TR?= M3nYdVQxdWmw MVnEUXNQ MnfiZoxw[2u|IFLOSGMh[2:vcH;1coR{KGmwZIXj[UBmgHCxc4Xy[UBw\iCyaH;zdIhifGmmeXzz[ZJqdmViYX7kJGRPSSCocnHncYVvfGG2aX;u MYeyNVk5OzJ7Nh?=
M-14 Mn:xRZBweHSxc3nzJGF{e2G7 NFLjdVczPc7:TR?= NV7Pc29VOC53aB?= MUZCpIlvcGmkaYTzJIJwfGhidHjlJINzfWSnIHX4eJJi[3RvIHHu[EBkd22yb4Xu[E1qdmS3Y3XkJIFxd3C2b4Ppdy=> MYGyNVk2PDl3OR?=
SK-BR-3 M{LkNGFxd3C2b4Ppd{BCe3OjeR?= NYnmUVNIPTEEoN88US=> Ml\DNog> MmPKZoxw[2u|IHHwc5B1d3SrYzDEUmEh\nKjZ33lcpRifGmxbjDpcoR2[2WmIHL5JINwdWKrbnH0bY9vKG:oIGPNMVE3PCCjbnSgdoFlcWG2aX;u M3G1elIyQTBzM{i2
MDA-MB-468 NV7BOpF7SXCxcITvd4l{KEG|c3H5 MorMOVDDqM7:TR?= NF\qbFIzcA>? NUfpSFV2[myxY3vzJIFxd3C2b4TpZ{BFVkFiZoLh[41mdnSjdHnvckBqdmS3Y3XkJIJ6KGOxbXLpcoF1cW:wIH;mJHNONTF4NDDhcoQhemGmaXH0bY9v MUeyNVkxOTN6Nh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
IRF-1 / p-STAT1 / cleaved PARP1 / cleaved-caspase3; 

PubMed: 27191889     


With the addition of Z-VAD-FMK, levels of cleaved Caspase-3 and PARP1 were decreased.

Beclin1 / Atg5 / Atg7 / LC-3I / LC-3II; 

PubMed: 27191889     


Levels of Beclin1, Atg5, Atg7 and LC3-II were decreased after IFN-γ stimulation. However, when IFN-γ was combined with the caspase inhibitor, levels of Beclin1, Atg5, Atg7 and LC3-II were not decreased as determined by the Western Blot test. 

p23 / Hsp90 / hTRET / MMP2; 

PubMed: 19740745     


Expression of Hsp90 client proteins during cell death. HeLa cells were preincubated with z-VAD-fmk (100 μM) for 1 h and exposed to various concentrations of tunicamycin (Tu, in μM) for 24 h. Cell extracts were prepared and analyzed by Western blotting. β-Actin was used as the loading control.

cyto C; 

PubMed: 17301139     


z-VAD-fmk did not inhibit cytochrome c release in RRV-infected MA104 cells (RRV: rhesus rotavirus). Mock- and RRV-infected MA104 cells either were not pretreated or were pretreated with 100 μM z-VAD-fmk for 2 h before RRV infection, and treatment was continued during infection. Fourteen hours after RRV infection, the cytosolic and heavy-membrane fractions were assayed for cytochrome c by Western blotting. Mock-infected MA104 cells were used as negative controls. Cox IV and tubulin were used as protein loading controls for the heavy-membrane and cytosolic fractions, respectively. Positions of molecular weight markers are indicated on the left.

27191889 19740745 17301139
Growth inhibition assay
Cell viability; 

PubMed: 12522090     


Inhibition of magnolol-induced apoptotic cell death by z-VAD-fmk. CH27 cells were treated with cell permeable broad-spectrum caspase inhibitor (z-VAD-fmk) 2 h prior to 80 μm magnolol treatment. Cell viability was estimated. ***P<0.001, compared with the 80 μM magnolol-treated group. 

12522090
Immunofluorescence
cytochrome c ; 

PubMed: 11726499     


Immunolocalization of Smac/DIABLO and cytochrome c in HeLa cells. (A-C) Viable (non-apoptotic) HeLa cells were stained with antibodies to cytochrome c (green) and Smac/DIABLO (red) as indicated. Note that both proteins clearly co-localize within punctate, mitochondrial structures. (D–F) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were UV-irradiated followed by further incubation for 8 h. Note the cells where cytochrome c has exited mitochondria and can be seen in a diffuse pattern throughout the cell, including the nucleus (white arrows). In the latter case, note the retention of Smac/DIABLO in punctate mitochondrial structures within the cytoplasm. (G-I) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were then treated with 10 µM actinomycin D for 8 h. Once again note the retention of Smac/DIABLO in mitochondrial structures. (J-L) HeLa cells were treated as described in (G-I). A close-up of a single cell that has undergone mitochondrial cytochrome c release, but where Smac/DIABLO is retained within mitochondria, is shown.

Smac/DIABLO; 

PubMed: 11726499     


Immunolocalization of Smac/DIABLO and cytochrome c in HeLa cells. (A-C) Viable (non-apoptotic) HeLa cells were stained with antibodies to cytochrome c (green) and Smac/DIABLO (red) as indicated. Note that both proteins clearly co-localize within punctate, mitochondrial structures. (D–F) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were UV-irradiated followed by further incubation for 8 h. Note the cells where cytochrome c has exited mitochondria and can be seen in a diffuse pattern throughout the cell, including the nucleus (white arrows). In the latter case, note the retention of Smac/DIABLO in punctate mitochondrial structures within the cytoplasm. (G-I) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were then treated with 10 µM actinomycin D for 8 h. Once again note the retention of Smac/DIABLO in mitochondrial structures. (J-L) HeLa cells were treated as described in (G-I). A close-up of a single cell that has undergone mitochondrial cytochrome c release, but where Smac/DIABLO is retained within mitochondria, is shown.

Endo G; 

PubMed: 12941691     


GFP-Bax expression and immunostaining of EndoG together with nuclear Hoechst staining in HeLa cells 18 h after transient transfection with a vector encoding GFP-Bax in the absence or in the presence of the caspase inhibitor z-VAD-fmk (100 μM). 

AIF; 

PubMed: 12941691     


GFP-Bax expression and immunostaining of AIF together with nuclear Hoechst staining in HeLa cells 18 h after transient transfection with a vector encoding GFP-Bax in the absence or in the presence of the caspase inhibitor z-VAD-fmk (100 μM). 

11726499 12941691
ELISA
IL-1β; 

PubMed: 26254306     


Cell-free medium supernatants were harvested at 5 h. IL-1β levels were measured by ELISA. Z-VAD-FMK was used as a positive control. Bars represent means ± sem of pooled results from 3 experiments performed in triplicate at different times.

26254306
In vivo In vivo Z-VAD-FMK administration has been shown previously to be nontoxic and to prevent apoptosis in animal models. Intraperitoneal HK-GBS injection leads to preterm delivery, and pretreatment with Z-VAD-FMK delays preterm delivery in mice. In OVA-sensitized mice,treatment of z-VAD-fmk inhibits allergen-induced leukocyte infiltration. Systemic injection of the pan-caspase inhibitor z-VAD-fmk immediately before OVA challenge reduced inflammatory cell accumulation, mucus hypersecretion, and Th2 cytokine release in OVA-sensitized/challenged mice. Treatment with z-VAD-fmk blocked terminal differentiation of lens epithelial cells and keratinocytes, the differentiation of monocytes into macrophages, and the differentiation of erythroid progenitors. z-VAD-fmk attenuated allergen-induced airway inflammation and hyperreactivity. Treatment with z-VAD-fmk in vivo also prevented subsequent T cell activation ex vivo[7].

Protocol

Cell Research:

[6]

- Collapse
  • Cell lines: human granulosa cell lines (GC1a, HGL5, COV434)
  • Concentrations: 50 μM
  • Incubation Time: 48 h
  • Method:

    To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.


    (Only for Reference)
Animal Research:

[7]

- Collapse
  • Animal Models: CD1 mice
  • Dosages: 10 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (198.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+35 %PEG 300+2%Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)C(C(=O)NC(C)C(=O)NC(CC(=O)OC)C(=O)CF)NC(=O)OCC1=CC=CC=C1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you suggest an in vivo formulation of S7023 for animal studies?

  • Answer:

    For in vivo study of S7023, The IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).

  • Question 2:

    What is difference between S7023 & S8102?

  • Answer:

    Unlike S7023, S8102 does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.

Caspase Signaling Pathway Map

Related Caspase Products

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID